Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

Concerns about the company's future growth are likely keeping investors away.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

While the process of re-opening government could yet take several days and the proposed Senate bill would only fund ...

Major U.S. equities indexes rose Monday afternoon amid optimism Congress could soon agree on a spending plan to end the ...